Compare CVS Health Corp (CVS) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Starbucks Corp — how do they compare? CVS Health Corp trades at $86.43 (market cap $112.49B), while Starbucks Corp trades at $93.14 (market cap $106.68B). The key difference: CVS Health Corp and Starbucks Corp are close in size by market cap, and CVS Health Corp pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Starbucks Corp for 190 Days on average.
| CVS | SBUX | |
|---|---|---|
Market Cap | $112.49B | $106.68B |
Volume | 8,467,392 | 9,406,993 |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $108.55 |
52-Week Low | $70.08 | $78.46 |
Typical Hold Time | 83 Days | 190 Days |
Enterprise Value | $174.83B | $125.51B |
Dividend Yield | 3.02% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Starbucks (SBUX) trades at $93.58, down 2.63% amid bearish technical signals and recent store closure announcements. The company shows mixed fundamentals with a high P/E ratio of 54.09 but strong recent earnings beats. Revenue growth remains modest at $37.18B for 2025, while net income declined to $1.86B. Analyst consensus remains positive with a $115.50 price target despite ongoing restructuring challenges and geopolitical tensions in China operations.
The stock faces near-term pressure from operational restructuring but maintains long-term growth potential through international expansion and brand strength. Key risks include labor relations, Chinese market exposure, and execution of store optimization strategy. With 47% analyst buy ratings and solid dividend payments, SBUX offers value for patient investors despite current headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
